{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"60.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Percentage of participants with sCR, CR, VGPR, and PR assessed by IMWG uniform response criteria. sCR: CR as defined plus normal FLC ratio \\& absence of clonal cells in bone marrow. CR: negative immunofixation on serum \\& urine; disappearance of any soft tissue plasmacytomas; \\<5 percentage (%) plasma cells in bone marrow; normal FLC ratio of 0.26-1.65. VGPR: serum \\& urine M-protein detectable by immunofixation; \\>=90% reduction in serum M-protein plus urine M-protein level \\<100 mg/24 hour (h); \\>90% decrease in difference between involved \\& uninvolved FLC levels required. PR: \\>=50% reduction of serum M-protein \\& reduction in 24h urinary M protein by \\>=90%/\\<200 mg/24 h; if serum \\& urine M-protein unmeasurable:\\>=50% decrease in difference between involved \\& uninvolved FLC; if serum \\& urine M-protein not measurable:\\>=50% reduction in plasma cells required, in place of M-protein.","groups":[{"description":"Participants received Isatuximab 10 mg/kg IV infusion QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 112 weeks).","id":"OG000","title":"Phase 1, Cohort 1: Isatuximab 10 mg/kg"},{"description":"Participants received Isatuximab 20 mg/kg IV infusion, QW for 4 weeks (i.e., on Day 1, Day 8, Day 15 and Day 22 of Cycle 1), and then Q2W (i.e., on Day 1 and 15) for subsequent treatment cycles (each cycle of 28 days) until unacceptable AEs, disease progression, or any other reason for discontinuation whichever occurs first (maximum duration of exposure: 137 weeks).","id":"OG001","title":"Phase 1, Cohort 2: Isatuximab 20 mg/kg"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on all treated population.","reportingStatus":"POSTED","timeFrame":"From the date of the first response until disease progression, or death due to any cause, whichever comes first (maximum duration of exposure: up to 112 weeks for Cohort 1 and 137 weeks for Cohort 2)","title":"Phase 1: Percentage of Participants With Overall Response (OR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}